Skip to main content

Advertisement

SpringerLink
Log in

Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Purpose

Peripheral T-cell lymphoma (PTCL) is an aggressive and heterogenous T-cell lymphoid malignancy. The prognostic value of C-reactive protein-to-albumin ratio (CAR) has never been assessed in PTCL.

Materials and methods

This study retrospectively reviewed the medical records of 76 patients diagnosed with various subtypes of PTCL. A CAR cutoff value of 0.794 was determined, and clinical outcomes, including response rate, overall survival (OS), and progression-free survival (PFS), were compared between the high (> 0.794) and low (≤ 0.794) CAR groups.

Results

After induction therapy, complete response was achieved in 8 (32.0%) and 39 patients (76.5%) in the high and low CAR groups, respectively. During the median follow-up of 57.5 months, the high CAR group had significantly worse 5-year PFS and 5-year OS rates. Even with adjustment for the International Prognostic Index (≥ 3), Prognostic Index for PTCL-unspecified (≥ 3), and T cell score (≥ 2), high CAR remained a significant prognostic factor for PFS (hazard ratio [HR]: 4.01, 95% confidence interval [CI] 2.04–7.86, p < 0.001) and OS (HR: 2.97, 95% CI: 1.33–6.64, p = 0.008).

Conclusion

CAR may play a complementary role in predicting prognosis in patients with PTCL, considering its simplicity, objectivity, and easy accessibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and materials

The datasets for this study are available upon reasonable request from the corresponding author.

References

  1. Laribi K, Alani M, Truong C, de Materre AB. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018;23(9):1039–53. https://doi.org/10.1634/theoncologist.2017-0524.

    Article  Google Scholar 

  2. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45(2):311–6. https://doi.org/10.1038/bmt.2009.165.

    Article  CAS  Google Scholar 

  3. Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851–66. https://doi.org/10.1111/bjh.14473.

    Article  CAS  Google Scholar 

  4. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008;111(12):5496–504. https://doi.org/10.1182/blood-2008-01-134270.

    Article  CAS  Google Scholar 

  5. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402–8. https://doi.org/10.1182/blood-2010-09-310342.

    Article  CAS  Google Scholar 

  6. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, et al. Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 2010;5(4):222–8. https://doi.org/10.1007/s11899-010-0062-x.

    Article  Google Scholar 

  7. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9. https://doi.org/10.1182/blood-2003-09-3080.

    Article  CAS  Google Scholar 

  8. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the international T cell project network. Br J Haematol. 2018;181(6):760–9. https://doi.org/10.1111/bjh.15258.

    Article  CAS  Google Scholar 

  9. Xu HJ, Ma Y, Deng F, Ju WB, Sun XY, Wang H. The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther. 2017;10:3059–70. https://doi.org/10.2147/OTT.S137002.

    Article  Google Scholar 

  10. Jung J, Lee H, Heo JH, Chang MH, Lee E, Park WS, et al. High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. Sci Rep. 2021;11(1):2674. https://doi.org/10.1038/s41598-021-82087-6.

    Article  CAS  Google Scholar 

  11. Di QS, Xu T, Song Y, Zuo ZG, Cao FJ, Yu XJ, et al. High C-reactive protein to albumin ratio predicts inferior clinical outcomes in extranodal natural killer T-cell lymphoma. Dose Response. 2020;18(2):1559325820917824. https://doi.org/10.1177/1559325820917824.

    Article  CAS  Google Scholar 

  12. Yang J, Guo X, Hao J, Dong Y, Zhang T, Ma X. The prognostic value of blood-based biomarkers in patients with testicular diffuse large B-cell lymphoma. Front Oncol. 2019;9:1392. https://doi.org/10.3389/fonc.2019.01392.

    Article  Google Scholar 

  13. Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 2018;18:119. https://doi.org/10.1186/s12935-018-0609-9.

    Article  CAS  Google Scholar 

  14. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. https://doi.org/10.1200/JCO.2013.54.8800.

    Article  Google Scholar 

  15. Budczies J, Klauschen F, Sinn BF, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12): e51862. https://doi.org/10.1371/journal.pone.0051862.

    Article  CAS  Google Scholar 

  16. Bento L, Díaz-López A, Barranco G, Martín-Morena AM, Baile M, Martín A, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish lymphoma group experience (GELTAMO). Br J Haematol. 2020;188(6):888–97. https://doi.org/10.1111/bjh.16263.

    Article  CAS  Google Scholar 

  17. Jung J, Lee H, Yun T, Lee E, Moon H, Joo J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Oncotarget. 2017;8(43):74975–86. https://doi.org/10.18632/oncotarget.20480.

    Article  Google Scholar 

  18. Bi XW, Wang L, Zhang WW, Yan SM, Sun P, Xia Y, et al. The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma. PeerJ. 2016;4: e1742. https://doi.org/10.7717/peerj.1742.

    Article  CAS  Google Scholar 

  19. Zhao Y, Shi Y, Shen H, Zhou D, Li L, Zhu J, et al. The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma. Leuk Lymphoma. 2020;61(3):623–30. https://doi.org/10.1080/10428194.2019.1700244.

    Article  CAS  Google Scholar 

  20. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https://doi.org/10.3389/fimmu.2018.00754.

    Article  CAS  Google Scholar 

  21. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155–70. https://doi.org/10.3109/10408363.2011.599831.

    Article  CAS  Google Scholar 

  22. Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151–8. https://doi.org/10.1016/j.clgc.2018.07.027.

    Article  Google Scholar 

  23. Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018;52:8–12. https://doi.org/10.1016/j.ejim.2018.04.014.

    Article  CAS  Google Scholar 

  24. Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. Am J Med. 2020;133(6):713-22.e7. https://doi.org/10.1016/j.amjmed.2019.10.031.

    Article  CAS  Google Scholar 

  25. Brenner DA, Buck M, Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest. 1990;85(1):248–55. https://doi.org/10.1172/JCI114419.

    Article  CAS  Google Scholar 

  26. Wei Y, Wei X, Huang W, Song J, Zheng J, Zeng H, et al. Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. Int J Hematol. 2020;111(5):681–5. https://doi.org/10.1007/s12185-020-02818-9.

    Article  CAS  Google Scholar 

  27. Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30–9. https://doi.org/10.1016/j.ctrv.2018.02.003.

    Article  Google Scholar 

  28. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–9. https://doi.org/10.1200/JCO.2005.03.6327.

    Article  CAS  Google Scholar 

  29. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):S41–7. https://doi.org/10.1080/10428190310001623775.

    Article  CAS  Google Scholar 

  30. Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–40. https://doi.org/10.1016/S0140-6736(18)32984-2.

    Article  CAS  Google Scholar 

Download references

Funding

This research was supported by the National Cancer Center research grant (no. 2110490-1).

Author information

Author notes

  1. Jongheon Jung and Ja Yoon Heo have contributed equally to this work and share first authorship.

Authors and Affiliations

  1. Center for Hematologic Malignancy, National Cancer Center, 323 Ilsan-Ro, Ilsandong-Gu, Goyang, Gyeonggi, 410-769, Republic of Korea

    Jongheon Jung, Eunyoung Lee, Hyewon Lee & Hyeon-Seok Eom

  2. Division of Oncology-Hematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Ilsan, Korea

    Ja Yoon Heo & Myung Hee Chang

  3. Department of Statistics, Dongguk University, Seoul, Korea

    Ju-Hyun Park

Authors
  1. Jongheon Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ja Yoon Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eunyoung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyewon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Myung Hee Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ju-Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyeon-Seok Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JJ and JYH designed the study, collected data, and drafted the manuscript. EL, HL, and MHC participated in the data collection and drafted the manuscript. J-HP performed statistical analyses. H-SE analyzed the results and drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hyeon-Seok Eom.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval and consent to participate

The study protocol was approved by the Institutional Review Board (IRB) (National Cancer Center 2020-0110, National Health Insurance Service Ilsan Hospital 2020-04-020) and complied with the Declaration of Helsinki. The requirement for informed consent was waived by the IRB, considering that no intervention was involved due to the retrospective nature of this study.

Patient consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 1900 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jung, J., Heo, J.Y., Lee, E. et al. Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma. Int J Hematol 117, 216–224 (2023). https://doi.org/10.1007/s12185-022-03474-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03474-x

Keywords

Search

Navigation